Cellares, founded in 2019, is a cell therapy manufacturer that strives to develop scalable solutions to accelerate care for people living with a range of diseases. The company is the first Integrated Development and Manufacturing Organization (IDMO), and its Cell Shuttle platform aims to use automation to increase productivity at facilities that manufacture cell therapies for both autologous and allogeneic processes. Cellares is headquartered in San Francisco, California.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
08/23/2023 | Series C-1 | $30.74MM | $xx.xx | $673.64MM | 8vc, Bristol Myers Squibb, Decheng Capital, Dfj Growth, Eclipse, Koch Disruptive Technologies, Willett Advisors | |
Price per Share
$xx.xx
Shares Outstanding
4,517,033
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
8vc, Bristol Myers Squibb, Decheng Capital, Dfj Growth, Eclipse, Koch Disruptive Technologies, Willett Advisors
|
||||||
08/23/2023 | Series C | $225MM | $xx.xx | $673.64MM | 8vc, Bristol Myers Squibb, Decheng Capital, Dfj Growth, Eclipse, Koch Disruptive Technologies, Willett Advisors | |
Price per Share
$xx.xx
Shares Outstanding
26,450,358
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
8vc, Bristol Myers Squibb, Decheng Capital, Dfj Growth, Eclipse, Koch Disruptive Technologies, Willett Advisors
|
||||||
05/05/2021 | Series B-1 | $2.01MM | $xx.xx | $241.05MM | 8vc, Decheng Capital, Eclipse Ventures, Skyviews Life Science | |
Price per Share
$xx.xx
Shares Outstanding
464,639
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
8vc, Decheng Capital, Eclipse Ventures, Skyviews Life Science
|
||||||
05/05/2021 | Series B | $80MM | $xx.xx | $241.05MM | 8vc, Decheng Capital, Eclipse Ventures, Skyviews Life Science | |
Price per Share
$xx.xx
Shares Outstanding
15,680,430
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
8vc, Decheng Capital, Eclipse Ventures, Skyviews Life Science
|
||||||
10/29/2020 | Series A | $18MM | $xx.xx | $45MM | 8vc, Eclipse Ventures, Ecor1 Capital | |
Price per Share
$xx.xx
Shares Outstanding
12,203,387
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
8vc, Eclipse Ventures, Ecor1 Capital
|